These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 16006928

  • 1. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.
    Fleshner N, Harvey M, Adomat H, Wood C, Eberding A, Hersey K, Guns E.
    J Urol; 2005 Aug; 174(2):636-41; discussion 641; quiz 801. PubMed ID: 16006928
    [Abstract] [Full Text] [Related]

  • 2. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
    Ströberg P, Hedelin H, Ljunggren C.
    Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
    [Abstract] [Full Text] [Related]

  • 3. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE.
    Ann Pharmacother; 2005 May; 39(7-8):1286-95. PubMed ID: 15941818
    [Abstract] [Full Text] [Related]

  • 4. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
    Dunn ME, Althof SE, Perelman MA.
    Int J Impot Res; 2007 May; 19(2):119-23. PubMed ID: 16738695
    [Abstract] [Full Text] [Related]

  • 5. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA.
    Am J Cardiol; 2005 Dec 26; 96(12B):42M-46M. PubMed ID: 16387566
    [Abstract] [Full Text] [Related]

  • 6. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Briganti A, Salonia A, Gallina A, Saccà A, Montorsi P, Rigatti P, Montorsi F.
    Nat Clin Pract Urol; 2005 May 26; 2(5):239-47. PubMed ID: 16474835
    [Abstract] [Full Text] [Related]

  • 7. [Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction].
    Aliaev IuG, Vinarov AZ, Akhvlediani ND.
    Urologiia; 2007 May 26; (1):45-6, 49. PubMed ID: 17471999
    [Abstract] [Full Text] [Related]

  • 8. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
    Mehrotra N, Gupta M, Kovar A, Meibohm B.
    Int J Impot Res; 2007 May 26; 19(3):253-64. PubMed ID: 16988721
    [Abstract] [Full Text] [Related]

  • 9. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S.
    Int J Impot Res; 2007 May 26; 19(3):281-95. PubMed ID: 17183346
    [Abstract] [Full Text] [Related]

  • 10. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
    Gupta M, Kovar A, Meibohm B.
    J Clin Pharmacol; 2005 Sep 26; 45(9):987-1003. PubMed ID: 16100293
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST.
    Pak J Pharm Sci; 2008 Jul 26; 21(3):275-81. PubMed ID: 18614424
    [Abstract] [Full Text] [Related]

  • 12. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D, Haro JM, Martin-Morales A, von Keitz A, Riley A, Bertsch J, Belger M, Wolka AM, Beardsworth A, EDOS Group.
    Int J Clin Pract; 2007 Nov 26; 61(11):1850-62. PubMed ID: 17850306
    [Abstract] [Full Text] [Related]

  • 13. Treatment of erectile dysfunction.
    Dinsmore W.
    Int J STD AIDS; 2004 Apr 26; 15(4):215-21. PubMed ID: 15075013
    [Abstract] [Full Text] [Related]

  • 14. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, Francis SH.
    Mol Pharmacol; 2006 Nov 26; 70(5):1822-31. PubMed ID: 16926278
    [Abstract] [Full Text] [Related]

  • 15. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH.
    Cardiol Rev; 2007 Nov 26; 15(2):76-86. PubMed ID: 17303994
    [Abstract] [Full Text] [Related]

  • 16. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
    Chang LL, Ma M, Allmen Hv, Henderson SC, Harper K, Hornbuckle K.
    Curr Med Res Opin; 2010 Jun 26; 26(6):1451-9. PubMed ID: 20394470
    [Abstract] [Full Text] [Related]

  • 17. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
    Shabsigh R, Seftel AD, Rosen RC, Porst H, Ahuja S, Deeley MC, Garcia CS, Giuliano F.
    Urology; 2006 Oct 26; 68(4):689-96. PubMed ID: 17070333
    [No Abstract] [Full Text] [Related]

  • 18. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
    Corbin JD, Beasley A, Blount MA, Francis SH.
    Neurochem Int; 2004 Nov 26; 45(6):859-63. PubMed ID: 15312980
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms.
    Grimsley SJ, Khan MH, Jones GE.
    Med Hypotheses; 2007 Nov 26; 69(1):25-6. PubMed ID: 17300876
    [Abstract] [Full Text] [Related]

  • 20. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V.
    Int J Impot Res; 2004 Jun 26; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.